What to know about MIGS for treating glaucoma

Minimally Invasive Glaucoma Surgery (MIGS) represents a significant advancement in the treatment of glaucoma, a group of eye conditions that damage the optic nerve and can lead to vision loss. MIGS procedures are designed to lower intraocular pressure (IOP), which is a major risk factor for glaucoma progression. Unlike traditional glaucoma surgeries such as trabeculectomy or tube shunt implantation, MIGS techniques offer a safer and less invasive alternative, making them suitable for patients with mild to moderate glaucoma.

MIGS procedures use microscopic-sized equipment and require only tiny incisions, often performed alongside cataract surgery. The goal is to enhance the eye's natural drainage systems to improve fluid outflow and reduce pressure. Common MIGS devices and techniques include the iStent, Hydrus Microstent, Xen Gel Stent, and the Kahook Dual Blade. These procedures typically result in quicker recovery times, fewer complications, and less postoperative care compared to traditional surgeries.

Patients undergoing MIGS often benefit from reduced dependence on glaucoma medications, which can be expensive and have side effects. While MIGS may not lower eye pressure as dramatically as traditional methods, their safety profile makes them an attractive option, particularly for earlier stages of the disease.

Not all patients are candidates for MIGS, and treatment decisions should be based on individual eye health, disease severity, and overall medical history. As technology advances, MIGS continues to evolve, offering new hope for millions living with glaucoma. For individuals seeking effective glaucoma management with fewer risks and a faster recovery, MIGS provides a promising alternative worth discussing with an ophthalmologist.